US Patent 10047375 Artificial nucleic acid molecules

Patent 10047375 was granted and assigned to CureVac on August, 2018 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Current Assignee

CureVac

Date Filed

June 28, 2016

Date of Patent

August 14, 2018

Patent Applicant

CureVac

Patent Application Number

15195934

Patent Citations Received

‌

US Patent 12109275 Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded protein

‌

US Patent 11834651 Method for producing and purifying RNA, comprising at least one step of tangential flow filtration

‌

US Patent 11865084 MERS coronavirus vaccine

‌

US Patent 11965000 Respiratory syncytial virus (RSV) vaccine

‌

US Patent 12083190 Rabies vaccine

‌

US Patent 10738306 Artificial nucleic acid molecules for improved protein or peptide expression

‌

US Patent 10898589 Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein

‌

US Patent 11661634 Method for producing RNA

‌

US Patent 11667910 Method for producing and purifying RNA, comprising at least one step of tangential flow filtration

‌

US Patent 11760992 Method for producing and purifying RNA, comprising at least one step of tangential flow filtration

•••

Patent Inventor Names

Andreas Thess

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

10047375

Patent Primary Examiner

‌

Nancy J Leith

Find more entities like US Patent 10047375 Artificial nucleic acid molecules

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API

By using this site, you agree to our Terms of Service.